Adalimumab, anti-IL-1β, and FAK inhibitors effectively blocked TNF-α, IL-1β, and reduced FAK activity; improved endothelial dysfunction caused by CAR-T cells, malignant cells, and myeloid cells in CAR-T cells treatment; and reduced endothelial leakage caused by CAR-T and other cells. Here, IL1B is linked to endothelial dysfunction.